DEUTERATED QUINAZOLINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Russian patent published in 2018 - IPC C07D473/34 A61K31/522 A61P35/00 A61P3/00 A61P29/00 A61P37/02 A61P31/14 A61P9/10 

FIELD: chemistry.

SUBSTANCE: present invention relates to a novel deuterated quinazolinone compound of formula (I) or a pharmaceutically acceptable salt thereof having the properties of a PI3K inhibitor. Compounds can be used to treat or prevent diseases such as cancer, cell proliferation disorders, inflammation, infections, autoimmune diseases. In formula (I)

R¹ and R² are independently hydrogen or halogen; R³ is selected from hydrogen, deuterium, CH₃, CH₂D, CHD₂, CD₃, CH₂CH₃, CD₂CH₃, CH₂CD₃ and CD₂CD₃; each of R⁴, R¹¹, R¹² and R¹³ independently represents hydrogen or deuterium; each of R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ independently represents hydrogen; provided that at least one of the R³, R⁴, R¹¹, R¹² or R¹³ is deuterated or is deuterium.

EFFECT: deuterated compounds of the present invention have increased activity as compared to non-deuterated or compounds deuterated to other positions.

10 cl, 1 tbl, 17 ex